Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
作者机构：Laboratory of Aging Research and Cancer Drug TargetState Key Laboratory of Biotherapy and Cancer CenterNational Clinical Research Center for GeriatricsWest China HospitalSichuan UniversityChengduChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)
年 卷 期：2019年第4卷第1期
页 面：63-101页
核心收录：
学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学]
基 金：This work is supported by the Excellent Youth Foundation of Sichuan Scientific Committee Grant in China(No.2019JDJQ0008) the National Major Scientific and Technological Special Project for“Significant New Drugs Development”of China(No.2018ZX09733001) the National Key Research and Development Program of China(No.2016YFA0201402)
主 题：epigenetic clinical drugs
摘 要：Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying *** dysregulation is often linked to human disease,notably *** the development of various drugs targeting epigenetic regulators,epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical *** this review,we summarize the aberrant functions of enzymes in DNA methylation,histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.
维普期刊数据库